Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim to build $65m US research facility

Will add new R&D operations to its US headquarters in Connecticut

Boehringer Ingelheim is expanding its R&D operations in the US with a new research and development facility.

The $65m facility will be located at the company's US headquarters in Ridgefield, Connecticut and when completed will handle production of active pharmaceutical ingredients used in early development activities.

It brings the total of Boehringer's investment in the US this year to $350m, adding to spending on projects such as a $42m new drug safety assessment building in Ridgefield and a $50m high containment operations facility in Columbus, Ohio.

J Martin Carroll, president and CEO of the company's US operations, said: “These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the US.”

“Through these investments we are improving our ability to research, develop and manufacture the medicines of tomorrow and in doing so fulfilling our promise to bring more health to patients and their families.”

15th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics